Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
J Thromb Haemost ; 8(11): 2530-41, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20723025

RESUMEN

BACKGROUND: Platelet activation by collagen depends on signals transduced by the glycoprotein (GP)VI-Fc receptor (FcR)γ-chain collagen receptor complex, which involves recruitment of phosphatidylinositol 3-kinase (PI3K) to phosphorylated tyrosines in the linker for activation of T cells (LAT). An interaction between the p85 regulatory subunit of PI3K and the scaffolding molecule Grb-2-associated binding protein-1 (Gab1), which is regulated by binding of the Src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP-2) to Gab1, has been shown in other cell types to sustain PI3K activity to elicit cellular responses. Platelet endothelial cell adhesion molecule-1 (PECAM-1) functions as a negative regulator of platelet reactivity and thrombosis, at least in part by inhibiting GPVI-FcRγ-chain signaling via recruitment of SHP-2 to phosphorylated immunoreceptor tyrosine-based inhibitory motifs in PECAM-1. OBJECTIVE: To investigate the possibility that PECAM-1 regulates the formation of the Gab1-p85 signaling complexes, and the potential effect of such interactions on GPVI-mediated platelet activation in platelets. METHODS: The ability of PECAM-1 signaling to modulate the LAT signalosome was investigated with immunoblotting assays on human platelets and knockout mouse platelets. RESULTS: PECAM-1-associated SHP-2 in collagen-stimulated platelets binds to p85, which results in diminished levels of association with both Gab1 and LAT and reduced collagen-stimulated PI3K signaling. We therefore propose that PECAM-1-mediated inhibition of GPVI-dependent platelet responses result, at least in part, from recruitment of SHP-2-p85 complexes to tyrosine-phosphorylated PECAM-1, which diminishes the association of PI3K with activatory signaling molecules, such as Gab1 and LAT.


Asunto(s)
Plaquetas/metabolismo , Colágeno/metabolismo , Proteína Adaptadora GRB2/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Animales , Plaquetas/citología , Fosfatidilinositol 3-Quinasa Clase Ia/metabolismo , Humanos , Proteínas de la Membrana/metabolismo , Ratones , Fosfoproteínas/metabolismo , Fosforilación , Activación Plaquetaria , Glicoproteínas de Membrana Plaquetaria/metabolismo , Proteína Tirosina Fosfatasa no Receptora Tipo 11/metabolismo , Transducción de Señal , Tirosina/química
2.
Br J Pharmacol ; 154(5): 918-39, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18587441

RESUMEN

Platelets have long been recognized to be of central importance in haemostasis, but their participation in pathological conditions such as thrombosis, atherosclerosis and inflammation is now also well established. The platelet has therefore become a key target in therapies to combat cardiovascular disease. Anti-platelet therapies are used widely, but current approaches lack efficacy in a proportion of patients, and are associated with side effects including problem bleeding. In the last decade, substantial progress has been made in understanding the regulation of platelet function, including the characterization of new ligands, platelet-specific receptors and cell signalling pathways. It is anticipated this progress will impact positively on the future innovations towards more effective and safer anti-platelet agents. In this review, the mechanisms of platelet regulation and current anti-platelet therapies are introduced, and strong, and some more speculative, potential candidate target molecules for future anti-platelet drug development are discussed.


Asunto(s)
Plaquetas/efectos de los fármacos , Enfermedades Cardiovasculares/tratamiento farmacológico , Drogas en Investigación/farmacología , Hemostasis/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Trombosis/tratamiento farmacológico , Animales , Plaquetas/metabolismo , Enfermedades Cardiovasculares/sangre , Diseño de Fármacos , Drogas en Investigación/uso terapéutico , Fibrinolíticos/farmacología , Humanos , Inhibidores de Agregación Plaquetaria/uso terapéutico , Transducción de Señal/efectos de los fármacos , Trombosis/sangre
3.
J Dairy Res ; 66(1): 73-80, 1999 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10191475

RESUMEN

The lactoperoxidase system is a naturally occurring antimicrobial system found in milk, with lactoperoxidase, thiocyanate and hydrogen peroxide as its components. The keeping quality of milk pasteurized at 72 degrees C for 15 s was found to be better than that of milk heated at 80 degrees C for 15 s. This agrees with previous findings and is usually attributed to heat shocking of spores. However, complete deactivation of lactoperoxidase occurred at 80 degrees C-15 s, whereas at 72 degrees C-15 s residual lactoperoxidase activity was approximately 70%, which may provide an alternative explanation. Higher levels of hypothiocyanite (the major antimicrobial agent produced by the lactoperoxidase system) were also detected in milk processed at 72 than at 80 degrees C, which supports the theory that the lactoperoxidase system has a role in the keeping quality of pasteurized milk. Of all the methods evaluated, titratable acidity and alcohol stability gave the most consistent estimates of keeping quality, while dissolved oxygen was a good indication of the onset of spoilage. Lactoperoxidase activity decreased with temperature more rapidly between 70 and 80 degrees C than is usual for an enzyme over a 10 deg C range.


Asunto(s)
Manipulación de Alimentos , Lactoperoxidasa/metabolismo , Leche/enzimología , Animales , Conservación de Alimentos , Calor , Peróxido de Hidrógeno/análisis , Leche/química , Control de Calidad , Tiocianatos/análisis , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...